Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Oct 22;14(11):2315.
doi: 10.3390/v14112315.

Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

Lucia Taramasso  1 , Antonio Falletta  2 , Elena Ricci  3 , Giancarlo Orofino  4 , Nicola Squillace  5 , Barbara Menzaghi  6 , Giuseppe Vittorio De Socio  7 , Chiara Molteni  8 , Giovanni Francesco Pellicanò  9 , Roberto Gulminetti  10 , Giordano Madeddu  11 , Eleonora Sarchi  12 , Francesca Vichi  13 , Benedetto Maurizio Celesia  14 , Paolo Bonfanti  5 , Antonio Di Biagio  1   2 ; CISAI Study Group
Affiliations
Observational Study

Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

Lucia Taramasso et al. Viruses. .

Abstract

The aim of the present study was to evaluate CD4/CD8 dynamics in patients on dolutegravir (DTG)-based two-drug regimens (2DRs) and compare them with DTG-containing triple-drug regimens (3DRs). A prospective observational study was performed in the context of the SCOLTA cohort. Experienced PWH with HIV-RNA < 50 copies/mL were included if they were on the DTG-2DR, the DTG + tenofovir/emtricitabine (TDF/FTC) regimen, the DTG + tenofovir alafenamide (TAF)/FTC regimen, or the DTG + abacavir/lamivudine (ABC/3TC) regimen; they were followed-up for at least one year. A total of 533 PWH were enrolled, 120 in the DTG + 3TC group, 38 in the DTG + protease inhibitors (PI) group, 67 in the DTG + rilpivirine (RPV) group, 49 in the DTG + TDF/FTC group, 27 in the DTG + TAF/FTC group, and 232 in the DTG + ABC/3TC group. After one year, the CD4/CD8 ratio significantly increased in the PWH treated with DTG + 3TC (+0.08 ± 0.26), DTG + TDF/FTC (+0.1 ± 0.19), and DTG + ABC/3TC (+0.08 ± 0.25). At two years, the CD4/CD8 increase was confirmed for PWH on DTG + TDF/FTC (+0.16 ± 0.28) and DTG + ABC/3TC (+0.1 ± 0.3). In the SCOLTA cohort, PWH on 2DRs experienced a CD4/CD8 increase only in the DTG + 3TC group. Controlled studies with longer follow-up will clarify the long-term immunological and clinical impacts of DTG-2DR.

Keywords: ART; CD4/CD8 ratio; dolutegravir; immune recovery; three-drug regimen; two-drug regimen.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest relevant to the present study.

Figures

Figure 1
Figure 1
CD4 and CD8 T cells and CD4/CD8 ratio dynamics in patients in treatment with Dolutegravir. Values that significantly changed compared to baseline (p < 0.05) are indicated in bold; p = n.s.—p value not significant. 3TC—lamivudine; ABC—abacavir; DTG—Dolutegravir; FTC—emtricitabine; PI—protease inhibitors; RPV—rilpivirine; TAF—tenofovir alafenamide; TDF—tenofovir disoproxil fumarate; T0—baseline; T1—six-month follow-up; T2—one-year follow-up; T3—eighteen-month follow-up; T4—two-year follow-up.
See this image and copyright information in PMC

References

    1. Antela A., Rivero A., Llibre J.M., Moreno S., RET Group Redefining therapeutic success in HIV patients: An expert view. J. Antimicrob. Chemother. 2021;76:2501–2518. doi: 10.1093/jac/dkab168. - DOI - PMC - PubMed
    1. Buell K.G., Chung C., Chaudhry Z., Puri A., Nawab K., Ravindran R.P. Lifelong antiretroviral therapy or HIV cure: The benefits for the individual patient. AIDS Care. 2016;28:242–246. doi: 10.1080/09540121.2015.1074653. - DOI - PubMed
    1. Guaraldi G., Milic J., Marcotullio S., Mussini C. A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV. J. Antimicrob. Chemother. 2020;75:3425–3432. doi: 10.1093/jac/dkaa329. - DOI - PubMed
    1. Llibre J.M., Hung C.-C., Brinson C., Castelli F., Girard P.-M., Kahl L.P., Blair E.A., Angelis K., Wynne B., Vandermeulen K., et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391:839–849. doi: 10.1016/S0140-6736(17)33095-7. - DOI - PubMed
    1. Saracino A., Bruno G., Scudeller L., Volpe A., Caricato P., Ladisa N., Monno L., Angarano G. Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio. AIDS Res. Hum. Retroviruses. 2014;30:1178–1184. doi: 10.1089/aid.2014.0080. - DOI - PubMed

Publication types

MeSH terms